Section Arrow
Quote
MXCT.NASDAQ
- MaxCyte
Quotes are at least 15-min delayed:2026/08/05 19:37 EDT
After Hours
Last
 1.06
-0.01 (-0.93%)
Bid
1.06
Ask
1.11
High 1.09 
Low 1.01 
Volume 809 
Regular Hours (Closed)
Last
 1.07
-0.04 (-3.60%)
Day High 
1.12 
Prev. Close
1.11 
1-M High
1.48 
Volume 
496.89K 
Bid
1.06
Ask
1.11
Day Low
1.07 
Open
1.11 
1-M Low
0.98 
Market Cap 
118.91M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 1.07 
20-SMA 1.19 
50-SMA 1.18 
52-W High 1.865 
52-W Low 0.6434 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.36/-0.30
Enterprise Value
135.39M
Balance Sheet
Book Value Per Share
1.57
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
9.29M
Operating Revenue Per Share
0.38
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
BJDXBluejay Diagnostics Inc.1.24+0.24+24.00%-- 
After Hours 1.25 +0.01 +0.81%
BSXBoston Scientific Corp47.74-1.35-2.75%20.57PE
After Hours 48.7 +0.96 +2.01%
AMIXAutonomix Medical Inc.12.1-7.4-37.95%-- 
After Hours 12.1 0 0.00%
ADGMAdagio Medical Holdings Inc.0.739-0.061-7.63%-- 
After Hours 0.7106 -0.0284 -3.84%
PACBPacific Biosciences of California1.3-0.14-9.72%-- 
After Hours 1.2902 -0.0098 -0.75%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.